NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: PhosphonicS Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability - An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries - Phosphonics.com
PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability

 

NewswireToday - /newswire/ - Abingdon, Oxford, United Kingdom, 2015/11/12 - An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries - Phosphonics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The recently launched Phos-Cat4 has been specially designed to be just as effective as the rest of the PhosphonicS acid catalyst range but offer even more stability.

The PhosphonicS range of catalysts, which are designed specifically to simplify and streamline processes, use patented technology for attaching a variety of functionalities to a silica backbone. This range of products can be considered as alternatives to traditional homogeneous acids, with all the same chemical characteristics, whilst also benefitting from all the advantages of an immobilised reagent. These clean, efficient catalysts can be used from lab to plant scale across a range of transformations including esterification, elimination, protection and deprotection, rearrangement, cyclisation and hydrolysis reactions.

Phos-Cat4’s key benefits include:

• Reduced operating costs no additional washes are required;
• Lower waste disposal costs reduced discharge minimises environmental impact;
• No additional purification required prevents formation of genotoxic by-product impurities associated with sulfuric acids;
• Reduced overall production costs catalysts can easily be recycled for reuse;
• Increased stability.

Features of the PhosphonicS acid catalyst product range include:

• Easy to handle, free flowing solid;
• High acid strengths comparable to traditional acids;
• High chemical and physical stability;
• No pre-treatment required, no swelling;
• Can be applied in either fixed-bed (continuous) or slurry (batch) mode.

Alongside the range of products PhosphonicS (phosphonics.com) provide, they also have a team of scientists available to support customers throughout the evaluation of their products. In-house screening and testing programs are available along with full engineering support services and customised research and development programmes.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PhosphonicS Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rob Gibbs - Phosphonics.com 
+44(0)12 3583 4466 rob.gibbs[.]phosphonics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PhosphonicS Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PhosphonicS Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)